Table 5.
Direct and indirect comparisons: absolute difference in events per 1000 patients treated*
| Comparison | Risk difference (95% CI) | |||
|---|---|---|---|---|
| Symptomatic venous thromboembolism | Clinically relevant bleeding | Major bleeding | Net clinical endpoint | |
| Direct comparisons: | ||||
| Rivaroxaban v enoxaparin | −5 (−9 to −1) | 9 (2 to 17) | 4 (−0.4 to 8) | −3 (−9 to 3) |
| Dabigatran v enoxaparin | −2 (−9 to 5) | 5 (−4 to 13) | −1 (−6 to 5) | −1 (−9 to 7) |
| Apixaban v enoxaparin | −1 (−4 to 2) | −8 (−15 to −1) | −1 (−7 to 5) | −1 (−6 to 3) |
| Indirect comparisons: | ||||
| Rivaroxaban v dabigatran | −3 (−11 to 4) | 5 (−7 to 16) | 4 (−2 to 11) | −2 (−12 to 9) |
| Rivaroxaban v apixaban | −4 (−9 to 1) | 18 (7 to 28) | 5 (−2 to 12) | −2 (−9 to 6) |
| Apixaban v dabigatran | 1 (−7 to 8) | −13 (−24 to −2) | 0 (−8 to 7) | 0 (−9 to 9) |
*Random effects model, events while receiving treatment.